Track market-moving stories before they get noisy

Subsea horizontal tree systems engineered to support reliable, optimized production in remote, ultra-deepwater environments Agreement expands Baker Hughes’ offshore operations in Angola, reinforcing its global subsea tree position HOUSTON and LONDON, June 25, 2026 (GLOBE NEWSWIRE) -- Baker Hughes (NASDAQ: BKR), an energy technology company, announced Thursday a significant award from Azule Energy to provide subsea production systems to support safe, efficient operations in Angola’s Greater PAJ development.

Under the agreement, Baker Hughes will supply its deepwater horizontal tree systems to optimize production in the ultra-deepwater, greenfield development. In addition, the company will supply subsea control modules and intervention workover control systems, along with associated connection, distribution and topside equipment. Baker Hughes will also provide integrated tooling and services to support installation, commissioning and ongoing production performance from its facilities in Angola, leveraging its local supply chain to increase efficiencies.

“Ultra-deepwater developments demand unmatched reliability and performance to ensure that production is safe, efficient and sustained over the life of the field,” said Baker Hughes Executive Vice President of Oilfield Services & Equipment Amerino Gatti. “By combining Baker Hughes’ industry-leading offshore production technology with expertise honed through decades of experience of operating Angola’s deepwater fields, we can help Azule optimize production and deliver energy more effectively across Sub-Saharan Africa.”

The company’s deepwater horizontal tree systems are engineered for ultra-deepwater environments with an operating threshold of up to 10,000 psi and depths of 10,000 feet. The system’s modular, configurable design allows for fit-for-purpose configuration and short-cycle deliveries that help accelerate first production and support long-term field performance.

Baker Hughes has extensive experience in Angola’s offshore energy sector, and the country is home to its largest subsea installed base in Sub-Saharan Africa.

Delivery of subsea trees is expected to begin in 2027.

About Baker Hughes
Baker Hughes (NASDAQ: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and conducting business in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner and more efficient for people and the planet. Visit us at bakerhughes.com.

For more information, please contact:

Media Relations

Brian Reynolds
+1 346-315-6663
[email protected] 

Investor Relations

Chase Mulvehill
+1 346-297-2561
[email protected]
   

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced completion of patient enrollment in its Phase 2 clinical study evaluating GLK-321 for the treatment of Demodex blepharitis. GLK-321 is an investigational drug candidate using Glaukos' proprietary iLution platform, a novel ophthalmic drug-delivery syste.

Collaboration with Fear Free and Zomedica reinforces Assisi Loop tPEMF™ therapy as a low-stress option for pets.

ANN ARBOR, MI / ACCESS Newswire / June 25, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the renewal of the alliance between the Assisi® brand and Fear Free, the initiative dedicated to preventing and alleviating fear, anxiety, and stress (FAS) in pets.

The renewed agreement reinforces a shared commitment to improving the emotional and physical wellbeing of companion animals by integrating innovative therapies with Fear Free's science-based approach to low-stress handling and care.

"Renewing our partnership with Fear Free reflects our continued dedication to transforming the veterinary experience for pets, pet parents, and veterinary professionals," said Mialisa Gluckert, Senior Director of Product Commercialization at Zomedica. "With the Assisi devices, we are helping practices and pet owners adopt solutions that reduce stress while improving clinical outcomes."

Through this collaboration, Zomedica and Fear Free will continue to:

Educate veterinary professionals on incorporating stress-reducing protocols alongside therapeutic technologies

Expand awareness of non-invasive treatment options, including tPEMF therapy, for pain and inflammation management

Support pet parents with products that promote calmer, more positive care experiences for their animals

The Fear Free certification programs and educational resources have transformed how veterinary teams approach patient care by prioritizing emotional wellbeing. The Assisi therapeutic devices, including the Assisi Loop®,Assisi EquiLoop®, DentaLoop®, Loop Lounge®, and Calmer Canine® products complement these efforts by offering drug-free solutions that can be administered comfortably in low-stress environments.

"Fear Free is committed to reducing Fear, Anxiety, and Stress (FAS) and improving the wellbeing of pets through emotionally considerate care. We are excited to continue our alliance with Zomedica and support solutions that can be incorporated into a lower-stress care experience," said Natalie Gruchow, Corporate Programs & Product Specialists at Fear Free.

The renewal underscores both organizations' ongoing mission to raise the standard of care within veterinary medicine while strengthening the human-animal bond.

For more information about the Assisi line of products, visit: https://zomedica.com/our-brands/assisi/

About Zomedica

Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi Loop® line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, the VetGuardian PLUS™ Zero TouchTM monitoring system and VETIGEL® hemostatic gel, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 17% in 2025 to $32 million and maintains a strong balance sheet with approximately $48 million in liquidity as of March 31, 2026. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.

About Fear Free

Founded in 2016, Fear Free is a recognized leader in improving the emotional wellbeing of animals by educating and empowering those who care for them to help prevent and alleviate Fear, Anxiety, and Stress (FAS). Through continuing education, certification programs, and practical tools, Fear Free supports veterinary teams, pet care providers, and pet caregivers worldwide in delivering compassionate care. With a growing global community, Fear Free continues to expand its impact on how care is delivered. Learn more at fearfree.com.

Follow Zomedica

Email Alerts: http://investors.zomedica.com

LinkedIn: https://www.linkedin.com/company/zomedica

Facebook: https://m.facebook.com/zomedica

X (formerly Twitter): https://twitter.com/zomedica

Instagram: https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward-Looking Statements

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether demand for development services will continue; the outcome of clinical studies; the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments; uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:

Zomedica Investor Relations
[email protected]
1-734-369-2555

SOURCE: Zomedica Corp.

-- Motorhome RV Sales, Profit Dollars and Profit Margins Improved Meaningfully Year Over Year --

-- Winnebago Towables Improved Share Results Through Product Refreshes and Execution --

— Barletta Continues to Expand Share of U.S. Aluminum Pontoon Market --

-- Company Updates Fiscal 2026 Guidance --

EDEN PRAIRIE, Minn., June 25, 2026 (GLOBE NEWSWIRE) -- Winnebago Industries, Inc. (NYSE: WGO), a leading manufacturer of outdoor recreation products, today reported financial results for the Fiscal 2026 third quarter ended May 30, 2026.

Third Quarter Fiscal 2026 Financial Summary

Net revenues of $698.7 million compared to $775.1 million in the third quarter of Fiscal 2025Gross profit of $94.9 million, representing 13.6% gross margin, compared to $106.0 million in the third quarter of Fiscal 2025Net income of $14.5 million, or $0.51 per diluted share; adjusted earnings per diluted share of $0.66 compared to adjusted earnings per diluted share of $0.81 in the third quarter of Fiscal 2025Adjusted EBITDA of $37.8 million, representing 5.4% adjusted EBITDA margin CEO Commentary
“Our teams continue to execute in a retail environment that remained challenging through the third quarter,” said President and Chief Executive Officer Michael Happe. “Industry retail demand was pressured by broader macro factors, including elevated fuel costs, geopolitical uncertainty, and weak consumer confidence which continued to drive cautious dealer ordering and tighter inventory management across the channel. In response, we stayed disciplined, aligning production closely with retail while continuing to advance our key product, operational and cost initiatives.

“We're seeing a mixed demand environment across the portfolio. In Motorhome RV, sales, profitability and market presence continue to improve, supported by sustained performance at Grand Design Motorized and solid execution at Newmar. New product introductions, expanding brand presence and improved profitability continue to strengthen our standing in the segment. In Towables RV, category demand remained muted during the quarter, particularly at higher price points where competitive and promotional activity remained elevated. At the same time, our newer, more accessible offerings such as Thrive and Access contributed to improved retail dollar share and stronger year-over-year financial performance within our Winnebago-branded portfolio. These results reflect both dealer commitment to our strategy and the positive reception to our refreshed product lineup.

In Marine, Barletta continues to perform well, maintaining consistent market share gains, reaching 9.3% on a trailing twelve-month basis through April, despite softer volumes in the quarter. This performance reflects continued consumer interest in its premium pontoons and an expanding product lineup, including the recent Sanza introduction.

“We delivered solid SG&A improvement year-over-year, while continuing to invest in Grand Design Motorized, and advancing footprint rationalization and capacity alignment actions within our RV businesses. While industry retail pressure in the quarter slowed the pace of improvement in field inventory turns, our focus remains on driving sustainable progress, which will require continued discipline around shipments and production.

"One of the most encouraging aspects of our performance this quarter was the stability of our gross margins despite a challenging retail environment, reflecting the strength of our product mix, pricing discipline and operational execution. We have remained focused on profitable market share, while our higher average selling prices continue to support a more resilient retail dollar share position. We are executing against the levers we control including product, brand, cost structure, and inventory discipline, positioning the business to deliver improved performance as conditions evolve.”

Third Quarter Fiscal 2026 Results

Net revenues were $698.7 million, a decrease of 9.9% compared to $775.1 million in the third quarter of Fiscal 2025, driven primarily by lower unit volume, partially offset by selective price adjustments and product mix. Unit volume trends reflected growth in the Motorhome RV segment, partially offset by declines in the Towable RV and Marine segments, as dealer ordering remained measured and production levels were closely aligned to retail demand.

Gross profit was $94.9 million, a decrease of 10.5% compared to $106.0 million in the third quarter of Fiscal 2025. Gross profit margin was consistent with prior year as higher input costs and deleverage were largely offset by selective price adjustments.

Selling, general and administrative expenses were $66.5 million, a decrease of 5.4% compared to $70.3 million in the third quarter of Fiscal 2025, primarily due to cost reduction initiatives.

Operating income was $23.0 million, a decrease of 23.9% compared to $30.2 million in the third quarter of Fiscal 2025.

Net income was $14.5 million, compared to $17.6 million in the third quarter of Fiscal 2025. Reported earnings per diluted share was $0.51, compared to $0.62 in the third quarter of Fiscal 2025. Adjusted earnings per diluted share was $0.66, a decrease of 18.5% compared to $0.81 in the third quarter of Fiscal 2025.

Consolidated Adjusted EBITDA was $37.8 million, a decrease of 18.7%, compared to $46.5 million in the third quarter of Fiscal 2025.

Third Quarter Fiscal 2026 Segments Summary

Towable RV

 Three Months Ended ($, in millions)May 30, 2026 May 31, 2025 Change(1) Net revenues$274.7   $371.7   (26.1)%Operating income$16.0   $29.7   (46.3)%Operating income margin 5.8 %  8.0 % (220)bps   (1) Amounts are calculated based on unrounded numbers and therefore may not recalculate using the rounded numbers provided.

Net revenues decreased primarily due to lower unit volume and a shift in product mix toward lower price-point models, partially offset by selective price adjustments.Operating income margin decreased primarily due to higher input costs, volume deleverage, and product mix, partially offset by selective price adjustments and cost containment initiatives. Motorhome RV

 Three Months Ended($, in millions)May 30, 2026 May 31, 2025 Change(1)Net revenues$320.7   $291.2   10.1%Operating income (loss)$9.6   $(3.2)  NMOperating income margin 3.0 % (1.1)% 410bps  (1) Amounts are calculated based on unrounded numbers and therefore may not recalculate using the rounded numbers provided.

NM: Not meaningful.

Net revenues increased primarily due to higher unit volume and selective price adjustments.Operating income margin increased primarily due to higher unit volume driven by new products and selective price adjustments, partially offset by higher input costs. Marine

 Three Months Ended
($, in millions)May 30, 2026 May 31, 2025 Change(1)
Net revenues$92.4  $100.7  (8.3)%Operating income$5.3  $9.4  (43.4)%Operating income margin 5.8%  9.3% (350)bps   (1) Amounts are calculated based on unrounded numbers and therefore may not recalculate using the rounded numbers provided.

Net revenues decreased primarily due to lower unit volume and product mix, partially offset by selective price adjustments.Operating income decreased primarily due to higher input costs and volume deleverage, partially offset by selective price adjustments. Balance Sheet and Cash Flow
As of May 30, 2026, cash and cash equivalents totaled $57.1 million. The Company had total outstanding debt of $442.9 million ($450.0 million of debt, net of debt issuance costs of $7.1 million) and working capital of $411.6 million. Cash flow provided by operating activities during the nine months ended May 30, 2026 was $26.2 million compared to cash flow used in operating activities of $52.5 million during the same period last year. Operating cash flow improved by $78.7 million year over year, shifting from a use of cash in the prior-year period to a source of cash in the current year.

Quarterly Cash Dividend
On May 15, 2026, the Company’s Board of Directors approved a quarterly cash dividend of $0.35 per share payable on June 24, 2026, to common stockholders of record at the close of business on June 10, 2026.

Outlook
For calendar year 2026, Winnebago Industries now expects North American RV wholesale shipments in the range of 290,000 to 310,000 units. Based on this outlook, the current business environment, and results through the first nine months of the fiscal year, Winnebago Industries is updating its Fiscal 2026 revenue and EPS guidance as follows:

Consolidated net revenues in the range of $2.65 billion to $2.75 billion;Reported earnings per diluted share in the range of $1.05 to $1.40 compared to the Company's prior expectations for reported earnings per diluted share in the range of $1.50 to $2.20; andAdjusted earnings per diluted share guidance in the range of $1.65 to $2.00(1) compared to a prior range of $2.10 to $2.80. The Company’s outlook takes into account prevailing trends in the RV sector, including the impacts from current policy and trade environment, competitive dynamics, shifts in consumer preferences, and key macroeconomic factors that may influence overall demand.

“Our outlook reflects a measured view of the environment,” Happe said. “We expect demand conditions to remain challenged in the near term, with continued variability across segments. The actions we are taking across our portfolio, cost structure and product roadmap position us to manage through the cycle and improve the earnings profile of the business over time, including further operational and capacity initiatives expected to begin benefiting performance as we move through fiscal 2027.”

Q3 FY 2026 Conference Call
Winnebago Industries, Inc. will discuss third quarter of Fiscal 2026 earnings results during a conference call scheduled for 9:00 a.m. Central Time today. Members of the news media, investors and the general public are invited to access a live broadcast of the conference call and view the accompanying presentation slides via the Investor Relations page of the Company's website at http://investor.wgo.net. The event will be archived and available for replay for the next 90 days.

About Winnebago Industries
Winnebago Industries, Inc. is a leading North American manufacturer of outdoor recreation products under the Winnebago, Grand Design, Chris-Craft, Newmar and Barletta brands, which are used primarily in leisure travel and outdoor recreation activities. The Company builds high-quality motorhomes, travel trailers, fifth-wheel products, outboard and sterndrive powerboats, pontoons, and commercial community outreach vehicles. Committed to advancing sustainable innovation and leveraging vertical integration in key component areas, Winnebago Industries has multiple facilities in Iowa, Indiana, Minnesota and Florida. The Company’s common stock is listed on the New York Stock Exchange and traded under the symbol WGO. For access to Winnebago Industries' investor relations material or to add your name to an automatic email list for Company news releases, visit http://investor.wgo.net.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including the business outlook and financial guidance for Fiscal 2026. Investors are cautioned that forward-looking statements are inherently uncertain and involve potential risks and uncertainties. A number of factors could cause actual results to differ materially from these statements, including, but not limited to general economic uncertainty in key markets and a worsening of domestic and global economic conditions or low levels of economic growth; availability of financing for RV and marine dealers and retail purchasers; competition and new product introductions by competitors; ability to innovate and commercialize new products; ability to manage our inventory to meet demand; risk related to cyclicality and seasonality of our business; risk related to independent dealers; risk related to dealer consolidation or the loss of a significant dealer; significant increase in repurchase obligations; ability to retain relationships with our suppliers and obtain components; business or production disruptions; inadequate management of dealer inventory levels; increased material and component costs, including availability and price of fuel and other raw materials; ability to integrate mergers and acquisitions; ability to attract and retain qualified personnel and changes in market compensation rates; exposure to warranty claims and product recalls; ability to protect our information technology systems from data security, cyberattacks, and network disruption risks and the ability to successfully upgrade and evolve our information technology systems; ability to retain brand reputation and related exposure to product liability claims; governmental regulation, including for climate change; increased attention to environmental, social, and governance matters, and our ability to meet our commitments; impairment of goodwill and trade names; risks related to our 2030 Convertible Notes and Senior Secured Notes, including our ability to satisfy our obligations under these notes; and changes in recommendations or a withdrawal of coverage by third party securities analysts. Additional information concerning certain risks and uncertainties that could cause actual results to differ materially from that projected or suggested is contained in the Company's filings with the Securities and Exchange Commission ("SEC") over the last 12 months, copies of which are available from the SEC or from the Company upon request. We caution that the foregoing list of important factors is not complete. The Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this release or to reflect any changes in the Company's expectations after the date of this release or any change in events, conditions or circumstances on which any statement is based, except as required by law.

Contacts
Investors: Joan Ondala
[email protected]
Media: Dan Sullivan
[email protected]

Winnebago Industries, Inc.
Footnotes to News Release  Footnotes:

(1) Fiscal 2026 adjusted EPS guidance primarily excludes the pretax impact of intangible amortization of approximately $22 million.

Winnebago Industries, Inc.
Condensed Consolidated Statements of Income
(Unaudited and subject to reclassification)
  Three Months Ended(in millions, except percent and per share data)May 30, 2026 May 31, 2025Net revenues$698.7  100.0% $775.1  100.0%Cost of goods sold 603.8  86.4%  669.1  86.3%Gross profit 94.9  13.6%  106.0  13.7%Selling, general, and administrative expenses 66.5  9.5%  70.3  9.1%Amortization 5.4  0.8%  5.5  0.7%Total operating expenses 71.9  10.3%  75.8  9.8%Operating income 23.0  3.3%  30.2  3.9%Interest expense, net 5.0  0.7%  6.7  0.9%Non-operating income —  —%  (0.4) (0.1)%Income before income taxes 18.0  2.6%  23.9  3.1%Income tax provision 3.5  0.5%  6.3  0.8%Net income$14.5  2.1% $17.6  2.3%        Earnings per common share:       Basic$0.51    $0.63   Diluted$0.51    $0.62   Weighted average common shares outstanding:       Basic 28.3     28.0   Diluted 28.4     28.4            Nine Months Ended(in millions, except percent and per share data)May 30, 2026 May 31, 2025Net revenues$2,058.8  100.0% $2,020.9  100.0%Cost of goods sold 1,789.3  86.9%  1,755.0  86.8%Gross profit 269.5  13.1%  265.9  13.2%Selling, general, and administrative expenses 204.7  9.9%  212.1  10.5%Amortization 16.2  0.8%  16.7  0.8%Total operating expenses 220.9  10.7%  228.8  11.3%Operating income 48.6  2.4%  37.1  1.8%Interest expense, net 16.3  0.8%  19.3  1.0%Loss on note repurchase 0.8  —%  2.0  0.1%Non-operating income (0.3) —%  (1.0) (0.1)%Income before income taxes 31.8  1.5%  16.8  0.8%Income tax provision 7.0  0.3%  4.8  0.2%Net income$24.8  1.2% $12.0  0.6%        Earnings per common share:       Basic$0.88    $0.43   Diluted$0.87    $0.42   Weighted average common shares outstanding:       Basic 28.2     28.3   Diluted 28.4     28.4     Amounts in tables are calculated based on unrounded numbers and therefore may not recalculate using the rounded numbers provided.
In addition, percentages may not add in total due to rounding.

Winnebago Industries, Inc.
Condensed Consolidated Balance Sheets
(Unaudited and subject to reclassification)
 (in millions)May 30, 2026 August 30, 2025Assets   Current assets   Cash and cash equivalents$57.1 $174.0Receivables, net 186.1  192.0Inventories, net 435.2  396.4Prepaid expenses and other current assets 32.9  29.8Total current assets 711.3  792.2Property, plant, and equipment, net 319.9  333.0Goodwill 484.2  484.2Other intangible assets, net 440.7  456.9Investment in life insurance 27.9  27.1Operating lease assets 37.2  41.6Other long-term assets 17.3  19.4Total assets$2,038.5 $2,154.4    Liabilities and Shareholders' Equity   Current liabilities   Accounts payable$113.5 $129.3Accrued expenses 186.2  197.8Total current liabilities 299.7  327.1Long-term debt, net 442.9  540.5Deferred income tax liabilities, net 11.4  5.9Unrecognized tax benefits 5.7  4.8Long-term operating lease liabilities 34.1  39.3Deferred compensation benefits, net of current portion 4.4  5.1Other long-term liabilities 5.9  7.0Total liabilities 804.1  929.7Shareholders' equity 1,234.4  1,224.7Total liabilities and shareholders' equity$2,038.5 $2,154.4  Winnebago Industries, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited and subject to reclassification)
  Nine Months Ended(in millions)May 30, 2026 May 31, 2025Operating activities   Net income$24.8  $12.0 Adjustments to reconcile net income to net cash provided by (used in) operating activities   Depreciation 28.8   28.7 Amortization 16.2   16.7 Amortization of debt issuance costs 1.9   2.3 Last in, first-out ("LIFO") expense (2.4)  (0.6)Stock-based compensation 15.8   12.2 Deferred income taxes 5.5   (0.7)Deferred compensation expense 0.5   — Loss on note repurchase 0.8   2.0 Asset impairment —   1.2 Restructuring and related costs 1.6   — Other, net (2.8)  (1.2)Change in operating assets and liabilities, net of assets and liabilities acquired   Receivables, net 6.0   (59.0)Inventories, net (36.3)  (38.5)Prepaid expenses and other assets 4.0   7.2 Accounts payable (16.9)  (15.8)Income taxes and unrecognized tax benefits (0.4)  4.3 Accrued expenses and other liabilities (20.9)  (23.3)Net cash provided by (used in) operating activities 26.2   (52.5)    Investing activities   Purchases of property, plant, and equipment (16.8)  (29.2)Proceeds from sale of property, plant, and equipment 5.4   2.1 Other, net 0.1   1.6 Net cash used in investing activities (11.3)  (25.5)    Financing activities   Borrowings on long-term debt 3.0   15.3 Repayments on long-term debt (103.0)  (175.2)Payments of cash dividends (30.1)  (29.3)Payments for repurchases of common stock (1.7)  (53.6)Other, net —   0.4 Net cash used in financing activities (131.8)  (242.4)    Net decrease in cash and cash equivalents (116.9)  (320.4)Cash and cash equivalents at beginning of period 174.0   330.9 Cash and cash equivalents at end of period$57.1  $10.5     Supplemental Disclosures   Income taxes paid, net$2.1  $2.3 Interest paid 13.3   17.3     Non-cash investing and financing activities   Capital expenditures in accounts payable$1.4  $3.9 Dividends declared not yet paid 11.4   10.5 Increase in lease assets in exchange for lease liabilities:   Operating leases 1.1   2.3 Finance leases —   0.2   Winnebago Industries, Inc.
Supplemental Information by Reportable Segment - Towable RV
(in millions, except unit data)
(Unaudited and subject to reclassification)
  Three Months Ended May 30, 2026 % of Revenues(1) May 31, 2025 % of Revenues(1) $ Change(1) % Change(1)Net revenues$274.7   $371.7   $(96.9) (26.1)%Operating income 16.0 5.8%  29.7 8.0%  (13.8) (46.3)%             Three Months EndedUnit deliveriesMay 30, 2026 Product Mix(2) May 31, 2025 Product Mix(2) Unit Change % ChangeTravel trailer 5,274 75.5%  6,569 69.2%  (1,295) (19.7)%Fifth wheel 1,709 24.5%  2,926 30.8%  (1,217) (41.6)%Total Towable RV 6,983 100.0%  9,495 100.0%  (2,512) (26.5)%             Nine Months Ended May 30, 2026 % of Revenues(1) May 31, 2025 % of Revenues(1) $ Change(1) % Change(1)Net revenues$830.5   $913.9   $(83.4) (9.1)%Operating income 38.2 4.6%  51.3 5.6%  (13.1) (25.6)%             Nine Months EndedUnit deliveriesMay 30, 2026 Product Mix(2) May 31, 2025 Product Mix(2) Unit Change % ChangeTravel trailer 15,350 73.0%  16,034 68.7%  (684) (4.3)%Fifth wheel 5,669 27.0%  7,302 31.3%  (1,633) (22.4)%Total Towable RV 21,019 100.0%  23,336 100.0%  (2,317) (9.9)%            Dealer Inventory(3)May 30, 2026   May 31, 2025   Unit Change % ChangeUnits 18,721    17,747    974  5.5%
  (1) Amounts are calculated based on unrounded numbers and therefore may not recalculate using the rounded numbers provided.
(2) Percentages may not add due to rounding differences.
(3) Data is based on the latest information available from our dealer partners and is subject to timing of reporting and other limitations.

Winnebago Industries, Inc.
Supplemental Information by Reportable Segment - Motorhome RV
(in millions, except unit data)
(Unaudited and subject to reclassification)
  Three Months Ended May 30, 2026 % of Revenues(1) May 31, 2025 % of Revenues(1) $ Change(1) % Change(1)Net revenues$320.7   $291.2    $29.5  10.1%Operating income (loss) 9.6 3.0%  (3.2) (1.1)%  12.7  NM             Three Months EndedUnit deliveriesMay 30, 2026 Product Mix(2) May 31, 2025 Product Mix(2) Unit Change % ChangeClass A 219 14.3%  288  20.1%  (69) (24.0)%Class B 517 33.7%  406  28.4%  111  27.3%Class C 797 52.0%  737  51.5%  60  8.1%Total Motorhome RV 1,533 100.0%  1,431  100.0%  102  7.1%             Nine Months Ended May 30, 2026 % of Revenues(1) May 31, 2025 % of Revenues(1) $ Change(1) % Change(1)Net revenues$933.9   $798.5    $135.3  16.9%Operating income (loss) 25.3 2.7%  (7.0) (0.9)%  32.2  NM             Nine Months EndedUnit deliveriesMay 30, 2026 Product Mix(2) May 31, 2025 Product Mix(2) Unit Change % ChangeClass A 705 16.2%  808  20.2%  (103) (12.7)%Class B 1,416 32.5%  1,158  29.0%  258  22.3%Class C 2,234 51.3%  2,031  50.8%  203  10.0%Total Motorhome RV 4,355 100.0%  3,997  100.0%  358  9.0%            Dealer Inventory(3)May 30, 2026   May 31, 2025   Unit Change % ChangeUnits 3,468    3,614     (146) (4.0)%  (1) Amounts are calculated based on unrounded numbers and therefore may not recalculate using the rounded numbers provided.
(2) Percentages may not add due to rounding differences.
(3) Data is based on the latest information available from our dealer partners and is subject to timing of reporting and other limitations.
NM: Not meaningful.

Winnebago Industries, Inc.
Supplemental Information by Reportable Segment - Marine
(in millions, except unit data)
(Unaudited and subject to reclassification)
  Three Months Ended May 30, 2026 % of Revenues(1) May 31, 2025 % of Revenues(1) $ Change(1) % Change(1)Net revenues$92.4   $100.7   $(8.3) (8.3)%Operating income 5.3 5.8%  9.4 9.3%  (4.1) (43.4)%             Three Months EndedUnit deliveriesMay 30, 2026   May 31, 2025   Unit Change % ChangeBoats 1,155    1,254    (99) (7.9)%             Nine Months Ended May 30, 2026 % of Revenues(1) May 31, 2025 % of Revenues(1) $ Change(1) % Change(1)Net revenues$264.1   $272.9   $(8.8) (3.2)%Operating income 14.3 5.4%  21.0 7.7%  (6.6) (31.6)%             Nine Months EndedUnit deliveriesMay 30, 2026   May 31, 2025   Unit Change % ChangeBoats 3,282    3,471    (189) (5.4)%            Dealer Inventory(2,3)May 30, 2026   May 31, 2025   Unit Change % ChangeUnits 3,175    3,069    106  3.5%  (1) Amounts are calculated based on unrounded numbers and therefore may not recalculate using the rounded numbers provided.
(2) Due to the nature of the Marine industry, this amount includes a higher proportion of retail sold units than our other segments.
(3) Data is based on the latest information available from our dealer partners and is subject to timing of reporting and other limitations.

Winnebago Industries, Inc.
Non-GAAP Reconciliation
(Unaudited and subject to reclassification)  Non-GAAP financial measures, which are not calculated or presented in accordance with accounting principles generally accepted in the United States (“GAAP”), have been provided as information supplemental and in addition to the financial measures presented in the accompanying news release that are calculated and presented in accordance with GAAP. Such non-GAAP financial measures should not be considered superior to, as a substitute for, or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented in the news release. The non-GAAP financial measures presented may differ from similar measures used by other companies.

The following table reconciles diluted earnings per share to Adjusted diluted earnings per share:

 Three Months Ended Nine Months Ended May 30, 2026 May 31, 2025 May 30, 2026 May 31, 2025Diluted earnings per share$0.51  $0.62  $0.87  $0.42 Amortization(1) 0.19   0.19   0.57   0.59 Loss on note repurchase(1) —   —   0.03   0.07 Asset impairment(1) —   0.04   —   0.04 Restructuring and related costs(1) —   —   0.06   — Gain on sale of property, plant and equipment(1) —   —   (0.10)  — Tax impact of adjustments(2) (0.04)  (0.05)  (0.12)  (0.16)Adjusted diluted earnings per share(3)$0.66  $0.81  $1.31  $0.96   (1) Represents a pre-tax adjustment.
(2) The company's non-GAAP income tax impact is calculated using an estimated tax rate for the U.S. of 22.0% for Fiscal 2026 and 23.0% for Fiscal 2025.
(3) Per share numbers may not foot due to rounding.

The following table reconciles net income to consolidated EBITDA and Adjusted EBITDA.

 Three Months Ended Nine Months Ended(in millions)May 30, 2026 May 31, 2025 May 30, 2026 May 31, 2025Net income$14.5 $17.6  $24.8  $12.0 Interest expense, net 5.0  6.7   16.3   19.3 Income tax provision 3.5  6.3   7.0   4.8 Depreciation 9.4  9.6   28.8   28.7 Amortization 5.4  5.5   16.2   16.7 EBITDA 37.8  45.7   93.1   81.5 Loss on note repurchase —  —   0.8   2.0 Asset impairment —  1.2   —   1.2 Restructuring and related costs —  —   1.6   — Gain on sale of property, plant and equipment —  —   (2.8)  — Non-operating income —  (0.4)  (0.3)  (1.0)Adjusted EBITDA$37.8 $46.5  $92.4  $83.7   Non-GAAP performance measures of Adjusted diluted earnings per share, EBITDA and Adjusted EBITDA have been provided as comparable measures to illustrate the effect of non-recurring transactions occurring during the reported periods and to improve comparability of our results from period to period. Adjusted diluted earnings per share is defined as diluted earnings per share adjusted for after-tax items that impact the comparability of our results from period to period. EBITDA is defined as net income before interest expense, provision for income taxes, and depreciation and amortization expense. Adjusted EBITDA is defined as net income before interest expense, provision for income taxes, depreciation and amortization expense and other pretax adjustments made in order to present comparable results from period to period. Management believes Adjusted diluted earnings per share and Adjusted EBITDA provide meaningful supplemental information about our operating performance because these measures exclude amounts that we do not consider part of our core operating results when assessing our performance.

Management uses these non-GAAP financial measures (a) to evaluate historical and prospective financial performance and trends as well as assess performance relative to competitors and peers; (b) to measure operational profitability on a consistent basis; (c) in presentations to the members of our Board of Directors to enable our Board of Directors to have the same measurement basis of operating performance as is used by management in its assessments of performance and in forecasting and budgeting for the Company; (d) to evaluate potential acquisitions; and (e) to ensure compliance with restricted activities under the terms of our asset-backed revolving credit facility and outstanding notes. Management believes these non-GAAP financial measures are frequently used by securities analysts, investors and other interested parties to evaluate companies in our industry.

Calix, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CALX PR Newswire

Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
—Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe—

Hannover, Germany, June 25, 2026 – The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC), the leading pan-European research network dedicated to advancing the understanding and treatment of bronchiectasis, announced today at the World Bronchiectasis Conference (WBC 2026), its intention to collaborate with Insmed Incorporated to evaluate brensocatib 25 mg – an oral, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1) – over three years in an open-label, single-arm, interventional study enrolling up to 3,000 patients with bronchiectasis across the United Kingdom, Spain, Germany, Belgium, France, and Italy.

The study will be designed to deepen understanding of the long-term use of brensocatib and whether it has the potential to modify the course of the disease. This research would expand upon the current evidence that demonstrated brensocatib slows lung function decline, a measure used to indicate slower disease progression. The intended study will also evaluate whether earlier, upstream use of the therapy is effective in further slowing the progression of bronchiectasis, with a plan to include well-validated endpoints, along with some novel composite endpoints.

"Building on ASPEN trial data showing that brensocatib 25 mg reduced exacerbation frequency, slowed lung function decline, and produced structural changes in the airways, this study through the EMBARC network will allow us to ask an even more ambitious question: whether intervening earlier in the disease course can do more than slow progression, but fundamentally alter its trajectory,” said lead study investigator James Chalmers, MBChB, Ph.D., Rhodes Chair of Experimental Therapeutics and Respiratory Physician, University of Oxford. “Over a three-year horizon, we have a real opportunity to understand whether earlier use of brensocatib can not only reduce the burden of exacerbations and slow disease progression, but even more profoundly, change the natural course of the disease. That is the question at the heart of this study, and the answer could help shape how we treat bronchiectasis in the future."

Bronchiectasis is a serious, chronic, and progressive inflammatory lung disease characterized by the permanent widening of the airways, leading to persistent bacterial infections, excessive mucus production, and recurrent pulmonary exacerbations. These exacerbations are associated with accelerated lung function decline and poor quality of life. Bronchiectasis affects approximately 600,000 people across Europe, and millions of people globally.

"EMBARC is one of the world's leading bronchiectasis research networks, and this collaboration reflects our commitment to understanding how brensocatib can make the greatest possible difference in patients' lives,” said Martina Flammer, M.D., MBA, Chief Medical Officer, Insmed. “As a recognized innovator in bronchiectasis, we are spearheading transformative research together with EMBARC and distinguished clinical experts. Together with the scientific and patient community, we are uniquely positioned to help shape clinical advancement – and by studying brensocatib earlier in the disease course and over the longer term in a large, heterogeneous population, we hope to give patients the best possible chance of preserving their lung health."

About EMBARC

The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) was established in 2012 as a collaborative group within the Respiratory Infections Assembly of the European Respiratory Society (ERS) with the objective of creating a European bronchiectasis registry, harmonizing existing databases, and identifying opportunities to raise the profile of bronchiectasis at an international level. EMBARC is a pan-European research network dedicated to improving the understanding, diagnosis, and treatment of bronchiectasis. It brings together leading clinicians and researchers from across Europe to conduct high-quality interventional research and clinical trials in bronchiectasis.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines—including two approved therapies to treat chronic, debilitating lung diseases—as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.

Media Contact
MC Services AG
Eva Bauer, Alexander Sälzer
Email: [email protected]
Phone: +49 89 210 228 0

FSK Investors Have Opportunity to Lead FS KKR Capital Corp. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire

Shares in Advanced Medical Solutions Group (AIM:AMS) rose 16% to 278.14p after the company agreed to a recommended cash takeover by H.B. Fuller, the US adhesives group, valuing it at about £659 million.

Under the terms, shareholders in AMS, the AIM-listed surgical adhesives and wound-care specialist, will receive 285 pence in cash for each share.

The offer represents a premium of 34.8% to the closing price of 212 pence on 20 May, the last trading day before the offer period began.

It implies an enterprise value of about £715 million.

H.B. Fuller, the world's largest pure-play adhesives maker and listed in New York, is buying AMS through a wholly owned subsidiary.

The US company said the deal would extend its reach across tissue bonding adhesives, tapes and dressings, and formulated biosurgicals, lifting its addressable market by $15 billion to $95 billion.

It expects to generate about $55 million, or roughly £41 million, in annual revenue and cost synergies by 2031, including the removal of public company costs and sourcing savings.

The transaction is expected to add about 100 basis points to the combined group's earnings margin within 24 months and increase annual revenue by around $300 million.

Founded in 1991 and based in Winsford, AMS employs more than 1,800 people across 22 locations and sells into more than 100 countries under brands including LiquiBand and RESORBA.

Chris Meredith, chief executive of AMS, said the deal underscored the strategic progress made over his 15 years leading the company and the strength of its product portfolio.

Celeste Mastin, chief executive of H.B. Fuller, described the acquisition as a rare opportunity to advance the evolution of its portfolio, with medical a core strategic growth market.

The AMS directors, advised by Evercore and Investec, intend to unanimously recommend the deal, which is to be effected through a scheme of arrangement.

The acquisition is subject to merger control and foreign investment approvals across several jurisdictions and is expected to complete by the end of 2026.

DALLAS--(BUSINESS WIRE)--Jacobs named a supplier on the UK Government Commercial Agency's Construction Professional Services 2 framework.

SOMERVILLE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), announces it has received FDA 510(k) clearances for two new Breast Suite1 functionalities:

Breast Arterial Calcification (BAC) Assessment, a tool applied to standard screening mammograms that automatically identifies breast arterial calcifications, a potential early indicator of cardiovascular disease;2Prior exam integration into ProFound Pro, which enables automatic processing of prior and current studies to track prior lesions and distinguish new lesions, with the goal of improving cancer detection rates and reducing recalls. ProFound Pro with prior exam integration will be brought to market as Mammo Dx.3 The two additions reinforce Breast Suite as the industry’s most comprehensive end-to-end breast imaging AI suite—a modular, interoperable portfolio of applications addressing real-world clinical needs across breast cancer screening and diagnostic pathways. Both newly FDA cleared functionalities are now commercially available in the United States.

“Our strategy has always centered around using AI to find disease early. BAC Assessment and Mammo Dx are proof points of that strategy: one adds a cardiovascular evaluation to a routine breast cancer screening mammogram and the other incorporates changes from past mammogram exams into current mammograms to improve cancer detection. Together, they transform Breast Suite into a fully integrated suite of solutions that give radiologists a more complete patient overview and added clinical confidence in two of the top causes of death in U.S. women,” said Niccolo Stefani, MD, Business and Product Leader, Population Health & Clinical AI, DeepHealth.

BAC Assessment analyzes standard 2D (FFDM) and 3D (DBT) mammograms, automatically identifying and flagging breast arterial calcifications within the radiology workflow with no additional imaging required beyond the mammogram. BACs visible on mammograms have been linked to an elevated risk of future cardiovascular events, including heart attacks and strokes.2 In clinical performance testing, DeepHealth’s BAC Assessment demonstrated more than 90% sensitivity and more than 88% specificity in identifying arterial calcifications across both dense and non-dense breast tissue.4 BAC Assessment is now commercially available and will be deployed across RadNet imaging centers in the U.S., providing additional real-world validation of its capability.

With the addition of prior exams, Mammo Dx enables the comparison of breast tissue over time amongst prior and current exams and helps radiologists identify subtle changes with lesions that may be undetected on a single-exam read. Mammo Dx brings prior findings into the interpretation process, supporting more informed clinical decision-making with the ultimate goal of helping reduce false positives and better determining when additional diagnostic procedures may be warranted.

With these clearances, DeepHealth’s Breast Suite now includes BAC Assessment, Mammo Dx for cancer detection and diagnosis, automated breast density assessment and future cancer risk assessment,5 alongside workflow tools that elevate radiologist performance and enhance operational efficiency. Today, components of Breast Suite support diagnostic accuracy6 and standardization of care7 across more than 10 million mammograms performed annually across the world.

About DeepHealth
DeepHealth is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for RadNet’s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in breast, chest, musculoskeletal, neuro, prostate and thyroid health. At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow. Thousands of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. Learn more at deephealth.com. 

About RadNet, Inc. 
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and/or operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members. Learn more at radnet.com. 

Forward Looking Statements
This communication contains certain “forward-looking statements” within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding our technology’s ability to stage-shift disease through proactive, timely intervention and discussions regarding our product features. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet, nor any of its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the technology. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes, and other risks and uncertainties described in the “Risk Factors,” “Management’s Discussion and Analysis,” and other sections of our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.

Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

DeepHealth Media Contact
Andra Axente
Director of Communications
+31614440971
[email protected]

RadNet Media Contacts 
Jane Mazur 
Senior Vice President, Corporate Communications 
+1 585-355-5978 
[email protected]

Mark Stolper
Executive Vice President and Chief Financial Officer
+1 310-445-2800

References

Breast Suite comprises multiple applications, including Mammo Dx, Breast Density, Safeguard Review, Risk Assessment, BAC Assessment, DeepHealth Viewer, Mammography Insights and Breast Ultrasound. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Mammography Insights is manufactured by Aquila, Inc. and distributed by DeepHealth, Inc. Any claims made about Breast Suite may reference claims associated with its individual components.Nandurkar et al., “Breast Arterial Calcification as a Predictor for Future Cardiovascular Events and Mortality: A Systematic Review and Meta-analysis,” Journal of Breast Imaging, 2026.The FDA-cleared software previously known as ProFound Pro is now marketed as Mammo Dx including priors. Mammo Dx retains the FDA-cleared capabilities of ProFound Pro and serves as the foundation for ongoing innovation, with additional features and enhancements being introduced over time.FDA 510(k) clearance K254131. Clinical Performance Testing.Not cleared for use in the U.S. Capability available in Europe.Louis, L. et al. “Equitable Impact of an AI-Driven Breast Cancer Screening Workflow in Real World US-wide Deployment.” Nature Health, 2025.McCabe et al. “Multistage AI-Driven Workflow Improves General Radiologist Screening Mammography Performance to the Level of Fellowship-Trained Breast Imagers: Real-world Evidence in >500,000 Patients.” RSNA Chicago. 2025.

SummaryCompaniesSubscription demand to increase as insurance options erode, analysts sayRivals are seeing growing demand for oral and cash-pay optionsDrugmakers benefit from selling to Hims' user baseNEW YORK, June 25 (Reuters) - Telehealth provider Hims and Hers Health (HIMS.N), opens new tab may get a boost next year from employers dropping coverage of weight-loss drugs like Novo Nordisk's (NOVOb.CO), opens new tab Wegovy and Eli Lilly's (LLY.N), opens new tab Zepbound and Foundayo ​to rein in costs, investors and analysts say.

Soaring use of the medications has pushed up costs for employers, some of whom plan to tell employees they will ‌no longer pay for them in 2027, industry experts say.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

Instead, employees are expected to purchase direct-to-consumer products which include subscriptions from telehealth companies like Hims that bundle appointments with providers and access to the medicines.

Analysts currently estimate Hims revenue at $2.89 billion this year and $3.45 billion for 2027. Seven analysts have raised 2026 estimates for the company since May, boosted in part by its deal with Novo to sell its drugs.

About a third ​of the company's revenue comes from its weight-loss business, and it's growing, said Raul Shah, CEO of DocShah Financial, which owns less than 1% of Hims shares.

"I project ​that ratio to continue increasing as more Americans partake in the GLP-1 mania," he said, adding that he sees the U.S. weight-loss market ⁠shifting away from relying on insurance coverage.

A spokesperson for Hims and Hers declined to comment.

EMPLOYERS PUSH EMPLOYEES OFFEmployer-based plans are the most prevalent source of health insurance in the United ​States, with over 150 million Americans enrolled in them, KFF data showed.

About 43% of employers covered the drugs for weight-loss in 2025, and estimates for 2026 are about the same.

But 10% of ​employers currently covering GLP-1 drugs for weight loss said they planned to drop the drugs in 2027, according to the Business Group on Health, a policy research group for large employers.

Truist analyst Jailendra Singh said employers are directly driving cash-pay activity, through benefit guides and by advertising platforms like TrumpRx and manufacturer pharmacies. Health insurer Cigna (CI.N), opens new tab is one example, dropping coverage of the medications for its own employees.

Novo Nordisk and Eli Lilly ​offer cash-pay pricing through their pharmacies NovoCare and LillyDirect. Novo's Wegovy and Lilly's Foundayo weight-loss pills start at $149 per month for cash pay.

NOVO'S NEW PARTNERHims had become one of the ​largest U.S. telehealth providers of weight-loss drugs, even after shifting from mass compounding of alternative versions of Novo and Lilly drugs. The company missed earnings and revenue targets last quarter as it adjusted to new compounding ‌rules with ⁠the branded drugs no longer in shortage.

Hims in March announced it would partner with Novo Nordisk for its branded drugs but would continue to sell compounded versions in special doses or formulations, as regulations allow.

Jamey Millar, executive vice president of U.S. operations at Novo Nordisk, said Hims and Hers has since brought in the most volume of its telehealth partners.

Analysts said it was too early to provide estimates on how many subscribers Hims gained from the Novo deal. Hims had 2.6 million subscribers in the first quarter, up 9% from the year-ago quarter.

"Second-quarter results ​should give us a little bit more perspective ​on how many new subscribers are joining ⁠the platform and how well the weight-loss portfolio is performing," said Morningstar analyst Keonhee Kim.

The majority of Hims' revenue comes from auto-renewed subscriptions, which for GLP-1 users cost $39 for the first month and $149 for following months. That comes with access to unlimited clinical consultations but does not ​include the cost of the medication.

Hims and Hers shares closed at $32.70 on Wednesday, down more than 50% from July of 2025, when ​they reached $72.

RIVALS SEE GROWING ⁠DEMANDRival telehealth companies including Noom, Ivim Health and Ro said they anticipate demand will continue to grow as prices fall.

A spokesperson for Columbus, Ohio-based Ivim said the company has seen a 345% increase in demand for the Wegovy pill since January. Ro has said the Wegovy pill has increased demand and brought in new customers, including men.

Because Hims already has a large, recurring customer base, the company ⁠provides drugmakers with ​a more appealing footprint than smaller rivals, analysts said.

Truist estimates that about 70% to 80% of new Hims ​weight-loss subscribers renew on a monthly basis, indicating it has remained competitive.

Facing a decline in corporate coverage, drugmakers like Novo may want to target people who are already at Hims and other subscription-based telehealth programs, rather than looking ​for additional patients itself.

"Pharma knows how to sell business to business," said Rajiv Leventhal, a healthcare analyst at commerce data firm eMarketer.

Reporting by Amina Niasse; editing by Caroline Humer and Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles., opens new tab

CORAL GABLES, Fla.--(BUSINESS WIRE)--Del Monte Corporation (NYSE: FDP), a global leader in fresh and shelf-stable produce, today announced that it will ring the Opening Bell at the New York Stock Exchange at 9:30 a.m. ET on Monday, June 29, 2026, marking the company's first day of trading under its new ticker symbol, DMC. The bell-ringing ceremony follows the company's recent corporate name change from Fresh Del Monte Produce Inc. to Del Monte Corporation and represents a significant milestone.

Although artificial intelligence (AI) is the hottest trend and largest addressable opportunity since the advent and proliferation of the internet in the mid-1990s, it's not the only innovation stirring investor interest and leading to eye-popping returns on Wall Street.

By one estimate, quantum computing can create up to $1 trillion in global economic value by 2035. This enormous addressable market has been the fuel behind the parabolic gains we've witnessed in pure-play quantum computing stocks IonQ (IONQ 7.62%), Rigetti Computing (RGTI 8.93%), and D-Wave Quantum (QBTS 8.81%).

We've also observed this trio of quantum computing stocks rallying from U.S. government contract wins and/or funding.

Image source: Getty Images.

But things may not be as perfect as their skyrocketing share prices over the last two years would suggest. Arguably, the biggest red flag comes from the insiders who know IonQ, Rigetti, and D-Wave best.

Insiders are telling a worrisome tale with their actions An insider is a high-ranking executive, board member, or beneficial owner of at least 10% of a company's outstanding shares who may possess non-public information.

By law, insiders are required to file any transactions of their company's stock, including the exercising of option contracts, within two business days. These Form 4 filings are also made for the sake of investor transparency.

Since quantum computing stocks really burst onto the scene two years ago, we've witnessed a decisive tilt in insider trading activity. Specifically, Form 4s show an abundance of net selling by insiders since June 18, 2024:

IonQ: $454.1 million in net selling Rigetti Computing: $71.5 million in net selling D-Wave Quantum: $331.1 million in net selling Collectively, the most in-the-know individuals at the three hottest pure-play quantum computing companies have sold nearly $857 million of their stock over the trailing two years.

Today's Change

(

-7.62

%) $

-4.41

Current Price

$

53.44

There is, however, a caveat to the above data that should be taken into consideration. Most executives and board members receive a significant portion of their compensation in stock and options. Insider selling to cover federal and/or state tax liability isn't something that investors should be overly concerned about.

But while there are several reasons for insiders to sell shares of their company, not all of which are inherently nefarious, there's only one reason for insiders to buy shares of their company's stock: the expectation that it'll rise.

Looking back over the same trailing two-year timeline, insider buying has been virtually nonexistent. Though IonQ has had roughly $2.25 million in cumulative insider purchases, D-Wave Quantum's insider buying tallies just $1,795 over the last two years, while Rigetti doesn't have a single insider purchase.

Today's Change

(

-8.93

%) $

-1.90

Current Price

$

19.38

One possible reason insiders are keeping their distance is the otherworldly valuations of quantum computing stocks. Though these companies offer breakneck growth potential in the coming years, their price-to-sales ratios are firmly in bubble territory, based on what history tells us.

Furthermore, game-changing technologies have a terrible early stage track record since the mid-1990s. Investors commonly overestimate how quickly innovations will be adopted and/or optimized by consumers and businesses. Quantum computing is still incredibly early in its adoption phase, and we're nowhere close to seeing businesses deploy quantum solutions to boost their sales and profits.

If insiders aren't buying, why should everyday investors?

PANews, June 25 – According to on-chain analyst Ai Yi’s monitoring, the “Hyperliquid whale who shorted 16 altcoins and made a $13.68 million profit” has begun selling ETH. Five hours ago, amid a market rebound, the whale deposited 6,855.13 ETH ($11.02 million) into Binance, likely to sell. This ETH was accumulated in February and March of this year at an average price of $1,991. If sold, it would result in a loss of $2.625 million.

Hyperliquid Portfolio Margin Feature Enters Beta Testing and Increases Limits

PANews June 25 news, according to Cointelegraph, the Hyperliquid portfolio margin feature has entered the beta testing phase and increased limits. Users with account value below $25 million can use BTC and HYPE as collateral to trade perpetual contracts, spot, and outcome markets.

Share to:

Author: PA一线

This content is for market information only and is not investment advice.

Follow PANews official accounts, navigate bull and bear markets together

Recommended Reading

Related Topics

According to Hyperinsight’s monitoring, SK Hynix officially announced its U.S. listing date today, targeting a July 10 debut on the NASDAQ. The company had previously disclosed a over $29 billion listing fundraising plan yesterday afternoon. Driven by listing optimism, SKHX surged 14% intraday, hitting $1930 at press time, with a daily trading volume of $407 million and open interest of $237 million. Since the news broke yesterday, 10 whales have built positions in SKHX on Hyperliquid, 9 of which opened long positions totaling around $21.27 million, at an average entry price of ~$1797.8 and average unweighted liquidation price of ~$1390.6. With price gains, all 9 long positions are now in unrealized profit. Market data shows that positions of over $1 million amount to roughly $140 million, with a long-short ratio (longs/shorts) of ~0.715. The average entry price for longs is ~$1672, while shorts average ~$1640. The nearest short liquidation threshold stands at $2149, just $200 away from the current price, mounting short-side pressure. -HyperInsight Bot is now live. Add @HyperInsightBot to your Telegram group, set it as admin (enable message sending permission) to auto-sync on-chain updates.

Relevant content

IBM Unveils World’s First Sub-1 Nanometer Chip Technology

According to market sources, IBM (IBM.N) has announced the world’s first sub-1-nanometer chip technology.

4 minutes ago

PlanB: Bitcoin is very likely to actually bottom out after falling below $53,000.

Renowned crypto analyst PlanB stated that Bitcoin will likely fall below its realized price (around $53,000) before hitting a genuine bottom, just as it did in every previous bear market. Currently, the curve representing the realized price has nearly overlapped with the black curve denoting the 200-week geometric moving average since 2023.

4 minutes ago

Institutions: Micron’s long-term agreements reduce industry cyclical volatility.

Quilter Cheviot strategist Ben Barringer said that Micron Technology’s extremely strong earnings show that the traditionally cyclical memory chip market is becoming more reliable. This performance further confirms the fact that demand for memory chips far outstrips supply. More importantly, Micron’s shift toward signing long-term agreements with clients provides the group with more stable profitability and makes it less vulnerable to sharp demand fluctuations. These long-term agreements actually set price ceilings and floors, require clients to commit to taking supply, and smooth out the historically highly cyclical market.

4 minutes ago

Analyst: Micron’s financial report indicates short-term fluctuations can be ignored as long as earnings prospects underpin its high valuation.

Senior Market Analyst Daniela Hathorn stated, "As Micron Technology's earnings report once again confirms that the AI investment cycle remains solid, the U.S. stock market has recouped some of its losses. This has boosted market sentiment across the entire semiconductor sector—after high-growth individual stocks underperformed earlier—indicating that as long as profit prospects continue to support high valuations, investors are still willing to overlook short-term fluctuations."

4 minutes ago

Circle partners with Nomura Securities to enter the Japanese yen foreign exchange settlement service market.

Stablecoin issuer Circle plans to collaborate with Nomura Securities to launch instant foreign currency settlement for Japanese corporate clients as early as 2027. The initiative will enable large cross-border transactions to be completed immediately, aiming to boost cross-border investment and trade. This will mark the first entry of a major stablecoin issuer into Japan’s corporate transaction market, allowing companies to convert yen into US dollar-denominated stablecoins for investment and instant transfers.

4 minutes ago

Institutions' Preview: Overview of US May Core PCE Price Index Monthly Rate

The US May core Personal Consumption Expenditures (PCE) Price Index monthly rate will be released tonight at 20:30 (UTC+8). Below are the forecasts from multiple institutions: Sumitomo Mitsui Banking Corporation: 0.2%; Royal Bank of Canada: 0.2%; JPMorgan Chase: 0.3%; Goldman Sachs Group: 0.3%; Bank of Montreal: 0.3%; Moody's Corporation: 0.3%; Standard Chartered: 0.3%; UniCredit: 0.3%; ING Group: 0.3%; HSBC Holdings: 0.3%; BNP Paribas: 0.4%; Wells Fargo: 0.4%; Capital Economics: 0.4%; Citigroup: 0.4%; Deutsche Bank: 0.4%; Nomura Securities: 0.4%; Pantheon Macroeconomics: 0.4%; Société Générale: 0.4%; Scotiabank: 0.4%; Morgan Stanley: 0.4%

4 minutes ago

2 hours ago

According to Hyperinsight monitoring, Cerebras (CBRS), the AI chip firm previously dubbed "Nvidia’s strongest challenger", saw its stock price fall in stages after reporting its first quarterly results since going public, as negative guidance overshadowed better-than-expected performance. The stock has dropped roughly 22% since the earnings release and officially broke below its IPO price today. On-chain whales are overall bearish. CBRS trades at $184 on the Hyperliquid platform, down 7.7% in 24 hours. Large-scale short positions (million-dollar level) total around $11.62 million, 2.39 times the long positions ($4.87 million). Two major short positions were placed precisely at high levels as early as the IPO day or even before the IPO: - Whale 0xe0ff: Shorted at $284.51 on May 14 with a 3x leveraged position of $6.13 million, generating an unrealized profit of $3.24 million (+104%); - Whale 0x9996: Shorted at $275.92 on May 11 with a 5x leveraged position of $5.48 million, generating an unrealized profit of $2.64 million (+162%). It is learned that both addresses currently hold short positions in both CBRS and SPCX, and have recorded substantial unrealized profits, preferring to place short positions at high levels before or on the day of major stock listings. With the realization of negative earnings news in this round, the combined unrealized profit of the two positions is around $5.88 million. Currently, the average entry price of CBRS short whales is around $275, and the current price is over 30% lower than that. The nearest short liquidation line is at $200.13, about 7% away from the current price.

Relevant content

IBM Unveils World’s First Sub-1 Nanometer Chip Technology

According to market sources, IBM (IBM.N) has announced the world’s first sub-1-nanometer chip technology.

4 minutes ago

PlanB: Bitcoin is very likely to actually bottom out after falling below $53,000.

Renowned crypto analyst PlanB stated that Bitcoin will likely fall below its realized price (around $53,000) before hitting a genuine bottom, just as it did in every previous bear market. Currently, the curve representing the realized price has nearly overlapped with the black curve denoting the 200-week geometric moving average since 2023.

4 minutes ago

Institutions: Micron’s long-term agreements reduce industry cyclical volatility.

Quilter Cheviot strategist Ben Barringer said that Micron Technology’s extremely strong earnings show that the traditionally cyclical memory chip market is becoming more reliable. This performance further confirms the fact that demand for memory chips far outstrips supply. More importantly, Micron’s shift toward signing long-term agreements with clients provides the group with more stable profitability and makes it less vulnerable to sharp demand fluctuations. These long-term agreements actually set price ceilings and floors, require clients to commit to taking supply, and smooth out the historically highly cyclical market.

4 minutes ago

Analyst: Micron’s financial report indicates short-term fluctuations can be ignored as long as earnings prospects underpin its high valuation.

Senior Market Analyst Daniela Hathorn stated, "As Micron Technology's earnings report once again confirms that the AI investment cycle remains solid, the U.S. stock market has recouped some of its losses. This has boosted market sentiment across the entire semiconductor sector—after high-growth individual stocks underperformed earlier—indicating that as long as profit prospects continue to support high valuations, investors are still willing to overlook short-term fluctuations."

4 minutes ago

Circle partners with Nomura Securities to enter the Japanese yen foreign exchange settlement service market.

Stablecoin issuer Circle plans to collaborate with Nomura Securities to launch instant foreign currency settlement for Japanese corporate clients as early as 2027. The initiative will enable large cross-border transactions to be completed immediately, aiming to boost cross-border investment and trade. This will mark the first entry of a major stablecoin issuer into Japan’s corporate transaction market, allowing companies to convert yen into US dollar-denominated stablecoins for investment and instant transfers.

4 minutes ago

Institutions' Preview: Overview of US May Core PCE Price Index Monthly Rate

The US May core Personal Consumption Expenditures (PCE) Price Index monthly rate will be released tonight at 20:30 (UTC+8). Below are the forecasts from multiple institutions: Sumitomo Mitsui Banking Corporation: 0.2%; Royal Bank of Canada: 0.2%; JPMorgan Chase: 0.3%; Goldman Sachs Group: 0.3%; Bank of Montreal: 0.3%; Moody's Corporation: 0.3%; Standard Chartered: 0.3%; UniCredit: 0.3%; ING Group: 0.3%; HSBC Holdings: 0.3%; BNP Paribas: 0.4%; Wells Fargo: 0.4%; Capital Economics: 0.4%; Citigroup: 0.4%; Deutsche Bank: 0.4%; Nomura Securities: 0.4%; Pantheon Macroeconomics: 0.4%; Société Générale: 0.4%; Scotiabank: 0.4%; Morgan Stanley: 0.4%

4 minutes ago

Hot feeds

Hot Articles

Follow us

HYPE printed a fresh all-time high near $77 in June 2026, then pulled back toward the mid-50s. With a fee-funded buyback engine pulling one way and a multi-year unlock pulling the other, $100 is possible but far from a given. Here is the realistic path, and what has to break right.

Summary

HYPE can reach $100 in 2026, but it is a bull-case outcome. Hyperliquid’s buyback engine creates real token demand from platform fees. The unlock schedule is the main force working against the buyback. Volume, regulation, ETF flows, and new markets decide whether the path opens. Hyperliquid’s HYPE token reached a new all-time high of roughly $77 in June 2026 before pulling back toward the mid-50s, and the move reignited the question its holders keep asking: can HYPE reach $100 before the year is out?

From the mid-50s, that target is a climb of roughly 70% to 80%, an ambitious but not absurd move for a token that has already delivered enormous gains since its late-2024 launch. The answer is not a simple yes or no, because HYPE sits at the center of an unusually clear tug-of-war.

On one side is a buyback engine that funnels almost all of the platform’s trading fees into buying and burning the token. On the other is a large multi-year schedule of token unlocks that keeps adding supply.

Whether HYPE hits $100 in 2026 depends on which of those forces wins, and on whether the platform’s growth catalysts arrive before its risks bite. This piece lays out the realistic path to that number, and the conditions that would have to break right for it to happen.

A note on what this is and is not: this is an analysis of scenarios and the forces that drive them, not a prediction presented as fact and not investment advice. Price targets in crypto are educated framings of probability, not promises, and anyone who tells you with certainty where a volatile token will trade in six months is guessing.

What follows covers where HYPE stands now, the buyback mechanism that gives it a structural floor, the supply overhang that opposes it, the growth catalysts that could power a run to triple digits, the risks that could cap it well short, what the broader market is actually betting, and three concrete scenarios, bull, base, and bear, for how 2026 could play out.

The goal is to give a holder a framework for thinking about the $100 question rather than a false promise about the answer.

Where HYPE stands right now Begin with the lay of the land, because the starting point shapes everything.

Hyperliquid is the dominant decentralized perpetual-futures exchange, a platform where traders take leveraged positions on crypto and, increasingly, on other assets, with its order book and matching engine running fully on its own high-performance blockchain.

Its token, HYPE, reached an all-time high near $77 in mid-June 2026 and has since corrected toward the mid-50s, giving it a market capitalization in the rough vicinity of $15 billion and a top-ten ranking among all cryptocurrencies.

That places HYPE among the most valuable tokens in the market, a remarkable ascent for an asset that launched at around $7.50 little more than a year and a half earlier. Hyperliquid also stands out because it was built without the usual venture-capital-heavy launch structure, with a large share of supply distributed to users instead of insiders.

The supply structure is central to any price discussion, so it is worth stating plainly. HYPE has a maximum supply approaching 1 billion tokens, but only a fraction of that, somewhere around a quarter, is currently circulating and tradeable.

The gap between the circulating supply and the eventual total is large, which means a great deal of HYPE is not yet on the market and will enter circulation over the coming years. This matters enormously for the $100 question, because price is a function of both demand and the supply it must absorb.

To reach $100 from the mid-50s, HYPE needs demand to grow faster than incoming supply. The entire bull-versus-bear debate around the token can be reduced to a single contest: the buyback engine adding demand on one side against the unlock schedule adding supply on the other.

Understanding both sides is the key to a grounded view of where HYPE can realistically go.

The buyback engine: HYPE’s structural floor The feature that makes HYPE unusual, and that anchors the bull case, is its buyback mechanism, which ties the token’s value directly to the platform’s success in a way few tokens can claim.

Hyperliquid directs the overwhelming majority of the trading fees its exchange generates, on the order of 97% to 99%, into a fund that continuously buys HYPE on the open market and removes it from circulation. In effect, the platform uses its revenue to repurchase its own token, much as a company might buy back its shares, creating a direct and automatic link between trading activity and token demand.

The more volume Hyperliquid handles, the more fees it collects, the more HYPE it buys, and the more upward pressure builds on the price. That makes the product driving Hyperliquid’s fees central to the investment case.

This is a genuinely powerful mechanism, because it grounds HYPE’s value in something concrete rather than pure speculation. Hyperliquid has processed trillions of dollars in cumulative trading volume and generated hundreds of millions in revenue, and it commands a dominant share of all on-chain perpetual trading.

That means the fee stream feeding the buyback is large and real.

For holders, the buyback acts as a kind of structural floor and a source of steady demand. As long as the platform keeps generating heavy volume, the fund keeps buying, which can offset selling pressure and support the price even in quiet markets.

It is the single strongest argument for HYPE reaching $100, because it converts the platform’s commercial success directly into token demand. But a floor is only as strong as the revenue beneath it, and the buyback has a formidable opponent on the other side of the ledger.

The supply overhang: the buyback’s opponent The force working against the buyback is the token unlock schedule, and it is substantial enough that no honest forecast can ignore it.

Because only about a quarter of HYPE’s eventual supply currently circulates, a large quantity of tokens, including allocations to the team and early contributors, is scheduled to unlock and enter the market gradually over a multi-year period stretching into the latter part of the decade.

Each unlock increases the circulating supply, and unless demand rises to match, that new supply weighs on the price. This is the central tension in HYPE’s structure: the buyback engine pulls supply out of circulation while the unlock schedule pushes new supply in, and the token’s trajectory depends on which force is stronger at any given moment.

For readers who want the base framework, reading HYPE’s unlock schedule starts with the tokenomics that decide whether demand is outrunning dilution.

The math of this contest is what determines whether $100 is reachable. If Hyperliquid’s trading volume stays high enough that the buyback removes tokens faster than, or at least as fast as, the unlocks add them, the net supply pressure stays manageable and demand growth can lift the price.

If volume falters, or if the unlocks accelerate beyond what the buyback can absorb, then per-token gains become constrained even if the platform’s overall value grows, because the same value is spread across more tokens.

This is the dilution risk, and it is the most important reason to temper expectations: a platform can succeed commercially while its token underperforms if supply growth outpaces the buyback.

So the buyback floor is real but conditional, and the condition is sustained, heavy trading volume. The entire $100 thesis rests on the buyback continuing to win its tug-of-war with the unlocks, which in turn rests on the catalysts that drive volume.

The growth catalysts that could power $100 For HYPE to reach $100, the buyback needs to keep winning, and that requires the platform’s volume and revenue to keep growing. That is where Hyperliquid’s expanding product surface comes in.

The most important catalyst is the opening of the platform to permissionless markets, a feature that lets third parties create their own perpetual-futures markets for assets beyond core crypto. Within months of launching, this capability was already generating a meaningful slice of the platform’s revenue and powering record trading days in markets for commodities such as silver and oil.

Expanding the universe of tradeable assets is the most direct way to grow volume, and therefore the most direct path to a higher token price.

Several other catalysts stack on top. The platform has been adding prediction-style markets and shorter-dated options, broadening its appeal beyond leveraged crypto traders to a wider audience.

Its full smart-contract layer lets outside developers build applications, vaults, and structured products on the same infrastructure, turning a single exchange into a programmable financial ecosystem and creating more activity that generates fees. Spot trading, real-world assets, and synthetic equities extend the platform further still.

That is why how on-chain exchanges work matters here: Hyperliquid is no longer only a perp venue, but a broader on-chain financial stack trying to pull more trading into one system.

One of the clearest examples is the growth of pre-IPO and synthetic private-market trading on Hyperliquid, including activity tied to SpaceX exposure through HIP-3 markets. That widens the platform beyond standard crypto pairs and shows how permissionless markets can turn outside narratives into fee-generating trading activity.

A new and potentially significant source of demand has also appeared in the form of regulated exchange-traded products that give traditional investors exposure to HYPE without holding it directly. Those products create another possible bid outside native crypto traders.

If these catalysts compound, each adding volume and fee revenue, the buyback grows more powerful, the supply pressure is more easily absorbed, and the path toward $100 opens. The bull case is essentially a bet that this product expansion keeps feeding the engine faster than the unlocks can drain it.

The risks that could cap it A grounded forecast has to weigh the catalysts against the risks, and HYPE faces several that could keep it well short of $100.

The most prominent is regulation. Hyperliquid operates in a legally gray area in some jurisdictions, including restrictions affecting access in the United States, and the traditional derivatives establishment has been pressing regulators to bring platforms like it under tighter oversight, citing concerns about manipulation and the kinds of permissionless markets that drive its growth.

A regulatory clampdown could limit the products Hyperliquid offers, impose new requirements that slow its expansion, or restrict its addressable market, any of which would cut into the trading volume that feeds the buyback. That is why the regulatory cloud over perp venues matters: the legal treatment of perpetual futures is no longer a side issue for platforms built around them.

Regulatory risk is the single largest external threat hanging over the token.

Competition is the second major risk. Hyperliquid commands a dominant share of on-chain perpetual trading, but that dominance invites attack, and large centralized exchanges, other decentralized venues, and new entrants are all chasing the same lucrative market.

If competitors replicate Hyperliquid’s features or undercut it on incentives, they can erode its market share and compress the trading fees that fund the buyback. Lower fees mean a weaker buyback, which means less support for the token.

Layered on these are the ordinary hazards of a crypto-market token. HYPE’s fortunes are tied to overall risk appetite, and in a risk-off environment, exchange tokens and high-beta assets tend to fall sharply regardless of fundamentals.

Perpetual-trading volume itself can also shrink when volatility and speculation dry up. So the risks form a coherent bear vector: regulation or competition shrinks volume, volume shrinks the buyback, the buyback can no longer outrun the unlocks, and the token’s supply pressure reasserts itself.

Any of these materializing would push $100 further out of reach.

What the market is actually betting It helps to see where the wider market lands on the $100 question, because the spread of opinion reveals how genuinely uncertain it is.

On prediction markets, where people bet real money on outcomes, the crowd in mid-2026 leaned toward HYPE surpassing $80 before year-end, with a smaller majority expecting it to clear $90, and a substantial minority, somewhat under half, betting it would exceed $100.

On the downside, bettors assigned high odds to HYPE trading below $50 at some point, reflecting awareness of the volatility and the unlock pressure. In other words, the market treats $100 as a real possibility but not the most likely outcome, with meaningful probability on both a strong run higher and a pullback lower.

Analyst forecasts span an even wider range, which is itself informative. Toward the cautious end, some firms project HYPE averaging in the high $30s to high $50s across 2026, essentially expecting the token to hold near or modestly above current levels.

In the middle, several see a return toward or past the all-time high if adoption continues. At the bullish extreme, one prominent investor has floated a target as high as $150, premised on the buyback engine, organic volume growth, and the expansion into prediction markets and options all firing together.

The enormous spread, from the high $30s to $150, is not a sign that the analysts are useless. It is an honest reflection of how much HYPE’s outcome depends on variables that are truly unknown, chiefly whether volume growth outpaces the unlocks and whether regulation intervenes.

The responsible reading of the consensus is that $100 is plausible in a strong scenario, roughly a coin-flip-or-worse proposition by year-end, and dependent on the bull catalysts materializing.

Bull, base, and bear scenarios for 2026 The cleanest way to hold all of this together is to lay out three scenarios, each with the conditions that would produce it, so the $100 question has context rather than a single false answer.

In the bull scenario, HYPE reaches and possibly exceeds $100. This requires the catalysts to compound: permissionless markets and new products driving trading volume sharply higher, the buyback consequently absorbing the unlocks with room to spare, exchange-traded product inflows adding a steady new bid, no serious regulatory blow landing, and a generally favorable crypto market providing tailwinds.

In that world, the buyback engine wins its tug-of-war decisively, demand outstrips the incoming supply, and the token reprices toward triple digits and beyond. It is a coherent path, but it requires most things to go right at once.

In the base scenario, the most probable of the three, HYPE spends 2026 trading in a wide band, roughly the mid-$40s to the low $70s, without a durable break to $100. Here the buyback and the unlocks roughly offset each other, volume grows but not explosively, and the token chops within range as catalysts and headwinds trade blows.

This is the unremarkable but likely outcome: a strong platform whose token consolidates after a big run, holding its value without delivering the parabolic move bulls hope for.

In the bear scenario, HYPE falls toward the $20s to low $40s. This is what a regulatory shock, a loss of market share to competitors, a slump in trading volume, or a broad risk-off downturn would produce, any of which would weaken the buyback and let the unlock supply drag the price down.

The key insight across all three is that $100 is specifically a bull-scenario outcome. It is not the base case, and it requires favorable conditions to align.

HYPE reaching $100 is possible. It is the optimistic branch, not the expected path.

The reflexive edge of the buyback, in both directions There is a subtler dynamic inside the buyback model that deserves attention, because it is what gives HYPE both its explosive upside and its hidden fragility: the mechanism is reflexive.

That means its parts feed back on one another in a loop that runs powerfully in whichever direction it is already moving. On the way up, the loop is a thing of beauty for holders.

Heavy trading volume generates large fees, the fees fund aggressive buybacks, the buybacks lift the price, the rising price draws attention and new traders to the platform, and that fresh activity generates still more volume and fees, which funds still more buying.

Each turn of the wheel reinforces the next, and in a strong market this is exactly how a token makes a 70% or 80% move toward a target like $100 look almost effortless. The buyback does not just support the price; it can compound a rally.

The trouble is that the same wheel turns in reverse with equal force. If trading volume falls, whether because of a market downturn, a regulatory blow, or competitors stealing share, the fees shrink, the buyback weakens, the diminished buying lets the price slide, the falling price dims the attention and excitement that drew traders in, and the quieter platform generates even less volume, which shrinks the fees further.

A virtuous circle becomes a vicious one, and the descent can be as self-reinforcing as the climb. This is the part of the buyback story that bullish framings tend to skip: a mechanism celebrated as a structural floor is only a floor while volume holds, and volume is exactly the thing that evaporates fastest when sentiment turns.

The buyback does not insulate HYPE from a downturn. In a real one, it can amplify the fall by weakening precisely when support is most needed.

For the $100 question, this reflexivity is the hinge that explains why the outcome is so binary and so dependent on conditions. In a favorable environment, the loop spins upward and $100 becomes very reachable, because demand feeds on itself.

In an unfavorable one, the loop spins downward and the token can fall far below current levels for the same self-reinforcing reason. There is less stable middle ground than a simple “buyback equals floor” story implies, because the model is built to accelerate moves, not to dampen them.

A holder betting on $100 is therefore betting not just that the platform grows, but that it grows in a market calm enough to let the reflexive engine spin upward without a shock large enough to throw it into reverse.

The buyback is a genuine edge, but it is an edge that cuts both ways, and respecting the downside is the difference between understanding HYPE and merely cheering for it.

So can HYPE reach $100 in 2026? Bringing it together, the honest verdict is that HYPE can reach $100 in 2026, but it is not the most likely outcome, and getting there requires a specific stack of things to go right.

The buyback engine has to keep winning its contest with the unlocks, which means trading volume has to stay heavy and ideally grow, powered by the platform’s expansion into new markets and products. A fresh source of demand, most plausibly exchange-traded products channeling outside capital in, has to add a sustained bid.

The major risks, regulation above all, then competition and a market downturn, have to stay contained. And the broader crypto market has to cooperate, because even the best token struggles to make a 70% to 80% move in a hostile tape.

When all of those align, the path to $100 is real and even straightforward, because the buyback turns volume into relentless token demand.

The realistic conclusion is one of conditional possibility instead of confident prediction. In a strong, catalyst-driven, risk-on 2026, $100 is achievable and the bull case is coherent.

In a flat or choppy year, the base case of wide-range consolidation is more likely, and the token holds its value without reaching the milestone. In a hostile year, the bear case pulls it well below current levels.

For a holder or watcher, the practical takeaway is to monitor the variables that actually decide it: Hyperliquid’s trading volume and fee revenue, the pace of unlocks against the pace of buybacks, the flows into the new exchange-traded products, and any movement on the regulatory front.

Those metrics, not any single price target, will tell you in real time whether HYPE is on the road to $100 or settling into its range. The number is reachable.

It is simply not promised, and anyone who treats it as a sure thing is ignoring the unlock schedule, the regulatory cloud, and the plain fact that crypto rarely moves in a straight line.

Frequently asked questions Can HYPE realistically reach $100 in 2026? It is possible but not the most likely outcome. From the mid-50s, $100 is a roughly 70% to 80% climb, achievable for a token this volatile but requiring favorable conditions to align: sustained high trading volume feeding the buyback, growth catalysts like new markets and exchange-traded products adding demand, contained regulatory risk, and a cooperative crypto market. $100 is best understood as a bull-scenario target instead of the base case, which is closer to wide-range consolidation in the mid-$40s to low $70s.

What is the HYPE buyback and why does it matter? Hyperliquid directs roughly 97% to 99% of its trading fees into a fund that continuously buys HYPE on the open market and removes it from circulation, similar to a company buying back its shares. This ties the token’s demand directly to the platform’s trading activity: more volume means more fees, more buybacks, and more upward pressure on the price. The buyback acts as a structural floor and is the strongest argument for HYPE rising, but it depends entirely on the platform maintaining heavy trading volume.

What is the biggest risk to HYPE’s price? Regulation is the largest external risk. Hyperliquid operates in a legal gray area in some jurisdictions, including access restrictions in the United States, and traditional derivatives firms have urged regulators to tighten oversight of platforms like it. A clampdown could limit its products, slow its growth, or shrink its market, cutting the trading volume that feeds the buyback. Competition eroding its market share and fees, and a broad crypto downturn reducing trading activity, are the other major risks that could cap the price.

Why does HYPE’s token unlock schedule matter? Only about a quarter of HYPE’s eventual supply currently circulates, with a large quantity scheduled to unlock gradually over several years. Each unlock adds supply, and unless demand rises to match, it weighs on the price. This creates HYPE’s central tension: the buyback removes tokens while unlocks add them. If trading volume keeps the buyback strong enough to absorb the unlocks, the price can rise; if volume falters and unlocks outpace buybacks, per-token gains are constrained even if the platform grows.

What are analysts predicting for HYPE in 2026? Forecasts span a very wide range, reflecting genuine uncertainty. Cautious projections see HYPE averaging in the high $30s to high $50s, essentially holding near current levels. Middle estimates expect a return toward or past its all-time high if adoption continues. The most bullish forecasts float targets as high as $150 if the buyback, volume growth, and new markets all fire together. Prediction markets in mid-2026 leaned toward HYPE clearing $80, with under half betting on $100.

What should I watch to judge where HYPE is heading? Track the variables that actually decide the outcome instead of any single price target. The most important is Hyperliquid’s trading volume and fee revenue, which power the buyback. Then watch the pace of token unlocks against the pace of buybacks, inflows into the new HYPE exchange-traded products, the platform’s expansion into new markets and products, and any regulatory developments affecting perpetual-trading venues. Those metrics will tell you in real time whether the buyback is outrunning supply and whether the path toward $100 is opening or closing.

This article is information, not investment advice. Price scenarios are uncertain framings, not predictions, and cryptocurrency is highly volatile. Figures for Hyperliquid and HYPE reflect reporting available as of June 25, 2026, and can change quickly. Do your own research and verify current data from primary sources before making any decision.

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against POET Technologies Inc. ("POET" or "the Company") (NASDAQ: POET) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between April 1, 2026, and April 27, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before June 29, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. POET misrepresented its tax status due to the likelihood it would be deemed a passive foreign investment company ("PFIC"), which would have negative tax implications for individual investors. The Company's business prospects were endangered by CFO Thomas Mika violating a business agreement in a public interview. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about POET, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.             

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com

Office: 310-301-3335

[email protected]

SOURCE The Schall Law Firm

PANews June 25 news, according to SoSoValue data, the crypto market fell for the third consecutive day. The Meme sector plunged 13.75% in 24 hours, with MemeCore (M) down 67.51% and Pump.fun (PUMP) down 10.90%; the NFT sector dropped 9.99%, within which Audiera (BEAT), which had surged yesterday, fell 22.63%. Meanwhile, Bitcoin (BTC) fell 3.36%, briefly dipping below $60,000 during the session; Ethereum (ETH) dropped 3.35%, falling to around $1,600.

In other sectors, the CeFi sector fell 2.33% in 24 hours, with NEXO (NEXO) down 3.59%; the PayFi sector dropped 3.18%, with Dash (DASH) down 7.82%; the Layer 1 sector fell 3.07%, but Gram (GRAM) bucked the trend with a 1.46% gain; the Layer 2 sector fell 3.46%, but Optimism (OP) rose 3.83%. Additionally, the DeFi sector stood out, rising 1.69%, with Hyperliquid (HYPE) up 2.04%, o1.exchange (O) up 35.42%, and LAB (LAB) up 19.60%.

Economist Peter Schiff framed gold’s selloff as a buying opportunity on Wednesday, while describing Bitcoin’s (CRYPTO: BTC) decline as a bubble that is “deflating.”

Schiff Says Dynamics Of Bitcoin And Gold Are DifferentIn an X post, Schiff stated that Bitcoin failed to rise alongside gold’s earlier gains, but is now declining in tandem—contrary to the expectations that a gold selloff would drive capital back into Bitcoin.

“While the drops are similar, the dynamics are different,” argued Schiff. “Gold’s selloff is a buying opportunity. Bitcoin’s selloff is a bubble deflating.”

Bitcoin In Free FallThe observation comes amid fresh turmoil in the Bitcoin market, with the leading cryptocurrency plunging below $60,000 for the first time in 20 months. The asset has collapsed by more than 52% from its all-time high of $126,198 in October of last year.

Schiff aggressively promotes gold as the ultimate safe-haven, while deriding Bitcoin as a worthless asset. However, 2026 has complicated this narrative.

Is Gold Really The Safe Haven In These Times?After a massive rally in 2025, gold experienced sharp volatility in the first quarter, including a dramatic March selloff of over 13%, its worst since the 2008 Financial Crisis. In fact, the yellow metal has plunged 24% since the outbreak of the Iran war, contrary to how a safe-haven is expected to perform.

And while Bitcoin has lagged behind gold over the past year, the cryptocurrency’s impressive gains over longer time horizons cannot be overlooked.

Citigroup predicted earlier this month that the yellow metal could fall another 20% by September.

Price Action: At the time of writing, BTC was exchanging hands at $61,707.47, down 1.43% in the last 24 hours, according to data from Benzinga Pro.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo courtesy: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

WSJ: Hyperscale Data Cash, Restricted Cash, Bitcoin, and Silver Assets of Approximately $94.8 Million Represents Approximately 100.42% of Market Capitalization of Common Stock

https://www.cnbc.com/2026/06/24/bitcoin-falls-back-under-60000-hitting-its-lowest-level-since-october-2024.html

Over $1 billion in cryptocurrency positions were liquidated in the last 24 hours as Bitcoin’s price fell to $59,175. This severe decline has impacted approximately 178,000 market participants, reflecting significant financial losses. The current downturn is attributed to multiple factors, including ETF outflows, major Bitcoin sales by Strategy Inc., and geopolitical tensions involving Iran. The price drop represents a substantial drawdown from Bitcoin’s peak of $126,000 in October 2025, marking its lowest level since late 2024. The $59,000–$60,000 range is now seen as a critical support area, with potential risks of a deeper correction if this level fails.

Advertisement

Key Takeaways Pricing suggests participants view the sub-$60,000 close as consistent with further downside risks. Market participants appear to be interpreting the recent liquidations as indicative of a larger leverage unwinding event. The significant drop in Bitcoin’s price suggests a reduced likelihood of reaching previous high targets like $90,000 in June. What to Watch Observers should monitor ETF flows and any further major sales by institutional entities, as these could influence Bitcoin’s price trajectory. Key economic indicators from the Federal Reserve, such as interest rate decisions, may also affect market perceptions and pricing. Watch for developments in geopolitical tensions, particularly involving Iran, which could add to market volatility. These factors could play a critical role in determining whether Bitcoin maintains or further declines from its current support level.

Get prediction market intelligence as a structured API feed. Early access waitlist.

Bitcoin Above On June 26 2026

Contract Odds Δ since publish Volume 24h June 26 99.4% — — View market → What Price Will Bitcoin Hit In June 2026

Contract Odds Δ since publish Volume 24h June 2026 0.1% — — View market → June 2026 0.2% — — View market → June 2026 0.4% — — View market → June 2026 18.9% — — View market → June 2026 7.3% — — View market → July 1 2026 1.9% — — View market → July 1 2026 0.1% — — View market → July 1 2026 0.1% — — View market → July 1 2026 2.6% — — View market → July 1 2026 1% — — View market → July 1 2026 0.7% — — View market → July 1 2026 0.2% — — View market → July 1 2026 0.1% — — View market → July 1 2026 0.1% — — View market → July 1 2026 0.5% — — View market → July 1 2026 1.1% — — View market → July 1 2026 5.8% — — View market → ⚡ Also Impacted by This Story

Bitcoin price predictions for june bearish

0% FLAT

Bitcoin (BTC) Headed to $42K Bottom in Late 2026, Says Leading Chinese Mining Executive

Table of contents

Last Updated: June 25, 2026

Bitcoin dropped to an intraday low of $59,102 on June 25, retesting the May 2026 cycle low as sellers pushed through the $61,620 support level. BTC is currently trading at $61,733, down 1.57% over 24 hours, with the 4H chart showing price recovering from the $59,102 wick but remaining below all three key moving averages.

Key Takeaways Bitcoin touched $59,102 intraday on June 25 — a direct retest of the May 2026 cycle low BTC is currently at $61,733, down 1.57% on the day; 24H high was $63,239 MA(7) at $61,247 | MA(25) at $62,931 | MA(99) at $63,679 — price trading below all three CLARITY Act Senate passage odds at 48% on Polymarket; August deadline is the last realistic window for 2026 BitMine Russell 1000 inclusion at market close June 26 — $2.15B estimated passive fund buying Bitcoin Price Metrics — June 25, 2026 MetricValueBTC Price (current)$61,73324h Change–1.57%24h High$63,23924h Low / Intraday Support Test$59,102MA(7)$61,247MA(25)$62,931MA(99)$63,679Cycle Low (May 2026)$59,130All-Time High (Oct 14, 2025)$126,173 Bitcoin Retests Cycle Low at $59,102 Bitcoin breached the $61,620 support level on June 25 and touched $59,102 intraday — directly retesting the cycle low established in May 2026. The wick below $60,000 triggered a wave of liquidations before buyers absorbed the move and pushed price back above $61,700.

The 4H chart shows BTC printing a recovery candle from the $59,102 low, but the structure remains bearish: price is trading below the MA(7) at $61,247, MA(25) at $62,931, and MA(99) at $63,679. A reclaim of MA(7) above $61,500 is the first step toward stabilization. Sustained recovery requires a close above MA(25) near $62,931.

If $59,102 fails on a closing basis, there is no meaningful technical support until the $55,000–$56,000 zone.

CLARITY Act in Crisis as August Deadline Looms The CLARITY Act’s Senate passage odds have fallen to 48% on Polymarket, with Galaxy Research revising its estimate to “roughly even.” Senator Lummis has warned that missing the August recess deadline effectively pushes the timeline to 2030. The bill still requires a 60-vote Senate floor threshold, reconciliation between two committee versions, and a presidential signature.

Regulatory uncertainty is applying direct pressure to XRP and the broader altcoin market, which had priced in a significantly higher probability of passage weeks ago.

BitMine Russell 1000 Inclusion: June 26 Catalyst BitMine joins the Russell 1000 at market close on June 26, with analysts estimating approximately $2.15 billion in forced passive fund buying. BitMine holds approximately 5.67 million ETH — nearly 5% of circulating supply — making the event a de facto Ethereum demand catalyst. The BTC price reaction on June 26 will depend on whether inclusion-driven ETH buying spills over into broad crypto sentiment.

A muted reaction would confirm the market already priced in the event. A sharp ETH rally could lift BTC alongside it.

Macro Context: Fed Hawkishness and Bessent Comments The Fed’s June 17 FOMC outcome — Chair Warsh with nine of eighteen officials projecting a rate hike and forward guidance eliminated — remains the dominant macro pressure on Bitcoin. Treasury Secretary Bessent told CNBC he does not put significant weight on the dot plot, projecting 3% or higher GDP growth in 2026, but the comments provided only a temporary bid for BTC before selling resumed.

A strong dollar and elevated rate expectations continue to pull institutional capital away from risk assets including Bitcoin and gold.

Bitcoin Price Analysis: Cycle Low Holds — For Now The $59,102 intraday wick is technically significant. On-chain data from earlier in the correction showed that the recent sell-off generated 234,000 BTC in realized losses — lower than the 400,000 BTC recorded at the prior capitulation. That divergence suggests weakening sell-side pressure, but a confirmed close below $59,102 would invalidate the pattern and open deeper downside.

Polymarket traders currently assign a 63% probability to Bitcoin finishing June 25 in the $60,000–$62,000 range. A daily close above $62,931 (MA(25)) is the minimum condition to shift near-term momentum back to neutral.

Bitcoin Price Comparison AssetPrice (June 25)7-Day ChangeBitcoin (BTC)$61,733–5.8%Ethereum (ETH)~$1,650–$1,670–5.8%XRP~$1.08–$1.11–10.0%Solana (SOL)~$69–6.4%BNB~$578–6.1%Polkadot (DOT)~$0.90–10.5% Where to Buy Bitcoin Binance — largest global exchange by volume, BTC/USDT with deep liquidity. Bybit — competitive spot and derivatives BTC pairs. Coinbase — regulated U.S. platform with institutional custody. Kraken — strong compliance track record. KuCoin — broad pair selection. Gate.io — wide token range. OKX — spot and futures with advanced order types.

FAQ What is Bitcoin’s price today, June 25, 2026?
Bitcoin is trading at approximately $61,733 on June 25, 2026, after touching an intraday low of $59,102 — a direct retest of the May 2026 cycle low. The price is down 1.57% over 24 hours and remains below its MA(7), MA(25), and MA(99) on the 4-hour chart, reflecting continued bearish structure.

Why did Bitcoin drop to $59,102 today?
Bitcoin’s drop to $59,102 on June 25 was driven by a combination of macro and regulatory headwinds: the Fed’s hawkish June 17 FOMC stance with projected rate hikes, falling CLARITY Act Senate passage odds from 74% to 48% on Polymarket, and the collapse of U.S.-Iran peace talks on June 19. The $61,620 support level broke under selling pressure, triggering liquidations that pushed price to the cycle low before buyers absorbed the move.

What is the CLARITY Act and why does it matter for Bitcoin?
The Digital Asset Market Clarity Act is U.S. market-structure legislation that would assign regulatory jurisdiction over digital assets, giving the CFTC oversight of Bitcoin and Ethereum as commodities. Senate passage odds stand at 48% on Polymarket. If the bill misses the August recess window, the next realistic opportunity is 2030, according to Senator Lummis.

What is the BitMine Russell 1000 inclusion and how does it affect crypto?
BitMine Immersion Technologies joins the Russell 1000 index at market close on June 26, 2026. Passive index funds must purchase BMNR shares proportionally, with analysts estimating $2.15 billion in forced buying. BitMine holds approximately 5.67 million ETH — nearly 5% of all circulating supply — making this a closely watched demand catalyst for Ethereum’s spot price.

What is Bitcoin’s all-time high?
Bitcoin’s all-time high is $126,173, reached on October 14, 2025. As of June 25, 2026, BTC trades approximately 51% below that record. The cycle low for the current correction was $59,102–$59,130, retested intraday on June 25.